Therapeutic Drug Monitoring for HIV

DO. SEE. HEAR. KNOW. Visit TheBody.com's 2008 World AIDS Day Center >>

BROWSE TOPICS IN HIV TREATMENT:

HIV Treatment: Home Page

Just Diagnosed

HIV Medications

First Steps to Treatment

HIV Drug Resistance

Switching or Stopping Treatment

Third Line/Rescue Treatment

Hepatitis C Coinfection

Women & Pregnancy

HIV Treatment for Children

Side Effects & Health Problems

Research & Experimental Drugs

HIV Treatment in the Developing World

Overview | Research

Show Archived (Historical) Articles

Overview

Drug Level Testing (February 14, 2006)
To read PDF, click here
From AIDS InfoNet
Therapeutic Drug Monitoring, or Integrating Antiretroviral Pharmacokinetics, HIV Resistance, and Genetics (July 2003)
Highlights from the IAPAC Sessions 2003.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
Therapeutic Drug Monitoring: The Next Best Thing in HIV Treatment? (Fall 2002)
To read PDF, click here
In STEP Perspective, from Seattle Treatment Education Project
Pharmacology: Drug Level Monitoring and Beyond (July 2001)
To read PDF, click here
From Project Inform
The Ups and Downs of Drug Levels: A Pharmacokinetics Primer (July/August 2001)
In GMHC Treatment Issues, from Gay Men's Health Crisis
Update on HIV Pharmacology and Therapeutic Drug Monitoring (July 2001)
From HIV InSite
The Ups and Downs of Drug Levels (May/June 2001)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
Therapeutic Drug Monitoring: Medscape Web Resource Page (March 30, 2001)
In AIDS Treatment News, from AIDS Treatment News
Editorial: Putting an End to the Guesswork (February 2001)
In HIV Newsline, from San Francisco General Hospital
Optimal Medical Management: Clinical Considerations in Therapeutic Drug Monitoring (February 2001)
In HIV Newsline, from San Francisco General Hospital
Optimal Medical Management: Entering the Era of Truly Individualized Antiretroviral Therapy (February 2001)
In HIV Newsline, from San Francisco General Hospital
The Relevance of Pharmacologic Monitoring in HIV Disease (December 2000)
In The PRN Notebook
Therapeutic Drug Monitoring (Autumn 2000)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
Some Unanswered Questions About Therapeutic Drug Monitoring (July 2000)
In TAGline, from Treatment Action Group

Research

Drug Level Monitoring Nearly Doubles Likelihood of Reaching Target Levels (December 17, 2007)
From aidsmap.com
Reducing the Dose of Lopinavir/Ritonavir Is Associated With Low-Level Viremia (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
New Research Explores Potential Value of Therapeutic Drug Monitoring (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Drug Monitoring and Pharmacology: More Mixes Nixed By Concentration Preoccupations (August 2004)
Highlights from a CROI 2004 post-conference workshop on drug-drug interactions.
In TAGline, from Treatment Action Group
Dosing Agenerase + Kaletra -- Trying to Juggle, Walk and Chew Gum All at the Same Time (March/April 2004)
A study presented at CROI 2004 bolsters support for the use of therapeutic drug monitoring to customize dosing.
In Positively Aware, from Test Positive Aware Network
To Measure or Not to Measure Drug Levels -- That Is the Question (March/April 2004)
Through the use of therapeutic drug monitoring, researchers are able to adjust patients' drug levels and reduce toxicity.
In Positively Aware, from Test Positive Aware Network
Drug Monitoring, NRTI Activity Help Predict Lopinavir/Ritonavir Response in Experienced Patients (February 11, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Importance of Resistance Testing and Therapeutic Drug Monitoring for Treatment Success (September 16, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
The Inhibitory Quotient in Tipranavir/Ritonavir (July 14, 2003)
Therapeutic drug monitoring and phenotypic resistance testing are also found to be a valuable predictor of response.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Plasma Protease Inhibitor Levels Can Mark Nonadherence (January 23, 2003)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Intracellular Metabolism of AZT Leads to the Production of Significant Levels of d4T Triphosphate in HIV Infected Patients (November 19, 2002)
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO
Therapeutic Drug Monitoring: Does It Make a Difference? (November 19, 2002)
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO
Phenotyping and Therapeutic Drug Monitoring Complement Genotyping in Optimizing Therapy for HIV Patients (October 26, 2002)
In 40th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
Hair Sample May Give Clues to HIV Drug Response (October 16, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Zidovudine and Lamivudine Seminal Plasma: Blood Plasma Concentration Ratios Do Not Predict Total SP Exposure (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO
The Role of Therapeutic Drug Level Monitoring in Clinical Practice (February 26, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
HAART and the Management of HIV-1 Infection: Can Short-Term Changes in the Plasma HIV-1 RNA Level Predict Long-Term Response to Therapy? (October 27, 2001)
In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
Therapeutic Drug Monitoring (TDM) of Nelfinavir (NFV) and Indinavir (IDV) In Treatment-Naive Patients Improves Therapeutic Outcome After 1 Year: Results from ATHENA (July 9, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Therapeutic Drug Monitoring: A Must for Clinical Practice? (July 9, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Therapeutic Drug Monitoring (Summer/Autumn 2001)
Report on the 2nd International Workshop on Clinical Pharmacology in HIV Therapy.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
The CSF Concentration/IC50 Ratio: A Predictor of CNS Antiretroviral (ARV) Efficacy (February 7, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Usefulness of Protease Inhibitor Therapeutic Drug Monitoring? PharmAdapt: A Prospective Multicentric Randomized Controlled Trial -- 12-Week Results (February 4, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Therapeutic Drug Monitoring in HIV Clinical Care (July 2000)
A report from the First International Workshop on Pharmacology in HIV Therapy.
In TAGline, from Treatment Action Group

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.